US Bancorp’s Silk Road Medical, Inc. Common Stock SILK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,080
Closed -$29.2K 4212
2024
Q2
$29.2K Buy
1,080
+73
+7% +$1.52K ﹤0.01% 2905
2024
Q1
$18.4K Hold
1,007
﹤0.01% 3132
2023
Q4
$12.4K Sell
1,007
-1,738
-63% -$16.3K ﹤0.01% 3242
2023
Q3
$41.1K Buy
2,745
+1,109
+68% +$23.1K ﹤0.01% 2543
2023
Q2
$53.2K Sell
1,636
-654
-29% -$23.9K ﹤0.01% 2474
2023
Q1
$89.6K Buy
2,290
+914
+66% +$44.7K ﹤0.01% 2245
2022
Q4
$72.7K Sell
1,376
-33
-2% -$1.61K ﹤0.01% 2337
2022
Q3
$63K Hold
1,409
﹤0.01% 2419
2022
Q2
$52K Sell
1,409
-264
-16% -$9.59K ﹤0.01% 2564
2022
Q1
$69K Buy
1,673
+489
+41% +$17.2K ﹤0.01% 2457
2021
Q4
$51K Buy
1,184
+137
+13% +$6.85K ﹤0.01% 2651
2021
Q3
$58K Buy
1,047
+117
+13% +$6.12K ﹤0.01% 2580
2021
Q2
$44K Buy
930
+508
+120% +$25.9K ﹤0.01% 2736
2021
Q1
$22K Buy
422
+97
+30% +$5.39K ﹤0.01% 2988
2020
Q4
$21K Hold
325
﹤0.01% 2899
2020
Q3
$22K Buy
325
+299
+1,150% +$16.3K ﹤0.01% 2784
2020
Q2
$1K Buy
+26
New +$998 ﹤0.01% 3669

Other funds holding SILK

US Bancorp's SILK Position: Q3 2024 in Review

US Bancorp sold out of Silk Road Medical, Inc. Common Stock (SILK) in Q3 2024, closing a stake of 1,080 shares — an estimated $29.2K sold.

US Bancorp first reported a position in SILK in Q2 2020 and held it in 17 quarters. The position peaked at $89.6K in Q1 2023. 1 fund tracked by Wall St. Rank holds SILK as of Q3 2024.

  • US Bancorp reported no remaining Silk Road Medical, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • US Bancorp sold 1,080 Silk Road Medical, Inc. Common Stock shares in Q3 2024, an estimated $29.2K.
  • US Bancorp first reported a position in Silk Road Medical, Inc. Common Stock in Q2 2020 and held it in 17 quarters.
  • US Bancorp's Silk Road Medical, Inc. Common Stock position peaked at $89.6K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Silk Road Medical, Inc. Common Stock as of Q3 2024.

Based on US Bancorp's 13F filing for Q3 2024, filed 28 Oct 2024.